rs797044441
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000388.4(CASR):c.186-1G>T variant causes a splice acceptor change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,524 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
NM_000388.4 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CASR | NM_000388.4 | c.186-1G>T | splice_acceptor_variant | ENST00000639785.2 | NP_000379.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASR | ENST00000639785.2 | c.186-1G>T | splice_acceptor_variant | 1 | NM_000388.4 | ENSP00000491584 | P1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461524Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 727102
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Nephrolithiasis/nephrocalcinosis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 04, 2018 | The c.186-1G>T intronic pathogenic mutation results from a G to T substitution one nucleotide upstream from coding exon 2 of the CASR gene. This mutation was detected in two family members with familial hypocalciuric hypercalcemia (FHH) and was not present in two unaffected individuals in the same family. Furthermore, functional studies performed at the RNA level showed that this mutation results in the skipping of exon 3 causing a frameshift that results in a premature stop codon leading to a predicted truncated protein of 153 amino acids (D'Souza-Li L et al. Hum. Mutat., 2001 Nov;18:411-21). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. - |
Familial hypocalciuric hypercalcemia 1 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Nov 01, 2001 | - - |
Autosomal dominant hypocalcemia 1;C1809471:Familial hypocalciuric hypercalcemia Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 15, 2023 | This sequence change affects an acceptor splice site in intron 2 of the CASR gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CASR are known to be pathogenic (PMID: 11807402, 14985373, 22422767). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with hypocalciuric hypercalcemia (PMID: 11668634). ClinVar contains an entry for this variant (Variation ID: 8342). Studies have shown that disruption of this splice site alters mRNA splicing and is expected to lead to the loss of protein expression (PMID: 11668634). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at